Zidovudine disposition during hemodialysis in a patient with acquired immunodeficiency syndrome.
Zidovudine (azidothymidine, AZT) disposition was examined during a hemodialysis session in an HIV-infected male with mesangial proliferative glomerulonephritis. Serum concentrations of zidovudine and its glucuronidated inactive metabolite (G-ZDV) were measured by HPLC. Zidovudine pharmacokinetics were similar to previous reports in patients with normal renal function, however, G-ZDV concentrations were significantly elevated (23-440 times zidovudine concentration). Hemodialysis did not appreciably reduce zidovudine or G-ZDV levels. Significance of chronically elevated G-ZDV levels is unknown.
Tartaglione
T A
TA
Department of Pharmacy, University of Washington, Seattle.
Holeman
E
E
Opheim
K
K
Smith
T
T
Collier
A C
AC
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000628:therapy; D006801:Humans; D008297:Male; D006435:Renal Dialysis; D015215:Zidovudine / Q000097:blood* / Q000627:therapeutic use
D015215:Zidovudine